{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:13:02Z","timestamp":1777137182975,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373717"],"award-info":[{"award-number":["82373717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117988","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:57:50Z","timestamp":1753113470000},"page":"117988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure-guided expansion strategy unveils potent allosteric SHP2 inhibitors with synergistic efficacy against AML through MCL-1 co-targeting"],"prefix":"10.1016","volume":"298","author":[{"given":"Maoqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feimeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxiao","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zequn","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhuo","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2025.117988_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117988_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117988_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/med.21890","article-title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery","volume":"42","author":"Song","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117988_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","article-title":"Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2","volume":"6","author":"Barford","year":"1998","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib5","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117988_bib6","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib8","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41467-018-06814-w","article-title":"Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2","volume":"9","author":"P\u00e1dua","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117988_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117988_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110317","article-title":"PD-L1\/SHP2 dual PROTACs inhibit melanoma by enhancing T-Cell killing activity","volume":"36","author":"Liu","year":"2025","journal-title":"Chin. Chem. Lett."},{"issue":"7610","key":"10.1016\/j.ejmech.2025.117988_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.ejmech.2025.117988_bib12","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117988_bib13","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2025.117988_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117988_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116579","article-title":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","volume":"275","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117988_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728222.2022.2066518","article-title":"Targeting SHP2 phosphatase in hematological malignancies","volume":"26","author":"Kanumuri","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117988_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1039\/D1MD00386K","article-title":"Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors","volume":"13","author":"Kong","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117988_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13402-022-00698-1","article-title":"A comprehensive review of SHP2 and its role in cancer","volume":"45","author":"Asmamaw","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2025.117988_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113264","article-title":"Targeting SHP2 as a therapeutic strategy for inflammatory diseases","volume":"214","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117988_bib22","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"issue":"13_Supplement","key":"10.1016\/j.ejmech.2025.117988_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-LB001","article-title":"Abstract LB001: anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers","volume":"81","author":"Koczywas","year":"2021","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117988_bib24","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J. Med. Chem."},{"issue":"16_suppl","key":"10.1016\/j.ejmech.2025.117988_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3020","article-title":"A First-in-Human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117988_bib26","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1021\/acs.jmedchem.4c00360","article-title":"Discovery of JAB-3312, a potent SHP2 allosteric inhibitor for cancer treatment","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"34","key":"10.1016\/j.ejmech.2025.117988_bib27","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted degradation of the oncogenic phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117988_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib30","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib31","article-title":"Discovery of novel SHP2 ATTEC degraders against pancreatic ductal adenocarcinoma harboring KRAS(G12D) mutations","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/14756366.2022.2151594","article-title":"Discovery of the SHP2 allosteric inhibitor 2-((3R,4R)-4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-5-(2,3-Dichlorophenyl)-3-Methylpyrrolo[2,1-f][1,2,4] Triazin-4(3H)-One","volume":"38","author":"Luo","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117036","article-title":"Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects","volume":"281","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib34","article-title":"Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors","volume":"279","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib35","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jcim.1c00075","article-title":"MolGpka: a web server for small molecule pKa prediction using a graph-convolutional neural network","author":"Pan","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.117988_bib36","article-title":"In silico modeling and scoring of PROTAC-mediated ternary complex poses","author":"Liao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115567","article-title":"A platform for the rapid synthesis of molecular glues (Rapid-Glue) under miniaturized conditions for direct biological screening","volume":"258","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41375-020-01083-3","article-title":"PTPN11 mutations are associated with poor outcomes across myeloid malignancies","volume":"35","author":"Swoboda","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117988_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110297","article-title":"Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development","volume":"93","author":"Krenz","year":"2022","journal-title":"Cell. Signal."},{"issue":"W1","key":"10.1016\/j.ejmech.2025.117988_bib40","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117988_bib41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib42","first-page":"1","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117988_bib43","article-title":"Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML","volume":"4","author":"Popescu","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"Supplement 1","key":"10.1016\/j.ejmech.2025.117988_bib44","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2023-184338","article-title":"SHP2 inhibition overcomes adaptive and acquired resistance to FLT3 TKI to improve efficacy against FLT3\/ITD AML","volume":"142","author":"Seale","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117988_bib45","article-title":"Chemical dissection of selective myeloid Leukemia-1 inhibitors: how they were found and evolved","volume":"283","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117988_bib46","series-title":"Amber 2020 Reference Manual","author":"Case","year":"2020"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117988_bib47","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117988_bib48","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theory Comput."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117988_bib49","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory Comput."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117988_bib50","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/ct400314y","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald","volume":"9","author":"Salomon-Ferrer","year":"2013","journal-title":"J. Chem. Theory Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:38:52Z","timestamp":1772771932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S0223523425007536"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117988","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided expansion strategy unveils potent allosteric SHP2 inhibitors with synergistic efficacy against AML through MCL-1 co-targeting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117988"}}